Asset Details
Do you wish to reserve the book?
Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial
Do you wish to request the book?
Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial
2002
Overview
In addition to its anti-ischaemic effects, the antianginal drug nicorandil is thought to have cardioprotective properties. We did a randomised trial to find out whether nicorandil could reduce the frequency of coronary events in men and women with stable angina and additional risk factors.
5126 patients were randomly assigned 20 mg nicorandil twice daily (n=2565) or identical placebo (n=2561) in addition to standard antianginal therapy. The primary composite endpoint was coronary heart disease death, non-fatal myocardial infarction, or unplanned hospital admission for cardiac chest pain. The secondary endpoint was the combined outcome of coronary heart disease death or nonfatal myocardial infarction. Other outcomes reported include all-cause mortality, all cardiovascular events, and acute coronary syndromes. Mean follow-up was 1·6 years (SD 0·5). Analysis was by intention to treat.
There were 398 (15·5%) primary endpoint events in the placebo group and 337 (13·1%) in the nicorandil group (hazard ratio 0·83, 95% Cl 0·72–0·97; p=0·014). The frequency of the secondary endpoint was not significantly different between the groups (134 events [5·2%] vs 107 events [4·2%]; 0·79, 0·61–1·02; p=0·068). The rate of acute coronary syndromes was 195 (7·6%) in the placebo group and 156 (6·1%) in the nicorandil group (0·79, 0·64–0·98; p=0·028), and the corresponding rates for all cardiovascular events were 436 (17·0%) and 378 (14·7%; 0·86, 0·75–0·98; p=0·027).
We showed a significant improvement in outcome due to a reduction in major coronary events by antianginal therapy with nicorandil in patients with stable angina.
Publisher
Elsevier Ltd,Lancet,Elsevier Limited
Subject
/ Angina
/ Angina Pectoris - classification
/ Angina Pectoris - drug therapy
/ Antianginal agents. Coronary vasodilator agents
/ Biological and medical sciences
/ Endpoint Determination - methods
/ Female
/ Heart
/ Humans
/ Male
/ Nicorandil - adverse effects
/ Nicorandil - therapeutic use
/ Nitrates
/ Pain
/ Patients
/ Pharmacology. Drug treatments
/ Therapy
